The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Oncogenic FGFR3 gene fusions in bladder cancer
Open accessAbstract
FGF receptor 3 (FGFR3) is activated by mutation or over-expression in many bladder cancers. Here, we identify an additional mechanism of activation via chromosomal re-arrangement to generate constitutively activated fusion genes. FGFR3-transforming acid coiled coil 3 (TACC3) fusions resulting from 4p16.3 re-arrangements and a t(4;7) that generates a FGFR3-BAI1-associated protein 2-like 1 (BAIAP2L1) fusion were identified in 4 of 43 bladder tumour cell lines and 2 of 32 selected tissue samples including the tumour from which one of the cell lines was derived. These are highly activated and transform NIH-3T3 cells. The FGFR3 component is identical in all cases and lacks the final exon that includes the phospholipase C gamma 1 (PLCγ1) binding site. Expression of the fusions in immortalized normal human urothelial cells (NHUC) induced activation of the mitogen-activated protein kinase pathway but not PLCγ1. A protein with loss of the terminal region alone was not as highly activated as the fusion proteins, indicating that the fusion partners are essential. The TACC3 fusions retain the TACC domain that mediates microtubule binding and the BAIAP2L1 fusion retains the IRSp53/MIM domain (IMD) that mediates actin binding and Rac interaction. As urothelial cell lines with FGFR3 fusions are extremely sensitive to FGFR-selective agents, the presence of a fusion gene may aid in selection of patients for FGFR-targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Singh, D., Chan, J. M., Zoppoli, P., Niola, F., Sullivan, R., Castano, A., Liu, E. M., Reichel, J., Porrati, P., Pellegatta, S., et al. (2012) · Science · doi:10.1126/science.1220834 · Cited by 789
Guagnano, V., Furet, P., Spanka, C., Bordas, V., Le Douget, M., Stamm, C., Brueggen, J., Jensen, M. R., Schnell, C., Schmid, H., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2006222 · Cited by 477
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P., Marsters, S., Stawicki, S., Tien, J., Totpal, K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38017 · Cited by 255
Lamont, F. R., Tomlinson, D. C., Cooper, P. A., Shnyder, S. D., Chester, J. D., & Knowles, M. A. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606016 · Cited by 180
Self-citationA TACC3/ch‐TOG/clathrin complex stabilises kinetochore fibres by inter‐microtubule bridging
Booth, D. G., Hood, F. E., Prior, I. A., & Royle, S. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.15 · Cited by 158
Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b
Bernard‐Pierrot, I., Brams, A., Dunois-Lardé, C., Caillault, A., de Medina, S. G. D., Cappellen, D., Graff, G., Thiery, J. P., Chopin, D. K., Ricol, D., et al. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi290 · Cited by 157
Hart, K. C., Robertson, S. C., & Donoghue, D. J. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.4.931 · Cited by 131
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer
Tomlinson, D. C., Hurst, C. D., & Knowles, M. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210399 · Cited by 128
Self-citationA Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges
di Martino, E., Tomlinson, D. C., & Knowles, M. A. (2012) · Advances in Urology · doi:10.1155/2012/429213 · Cited by 121
Self-citationIntegrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes
Duncan, C. G., Killela, P. J., Payne, C. A., Lampson, B. L., Chen, W., Liu, J., Solomon, D. A., Waldman, T. A., Towers, A. J., Gregory, S. G., et al. (2010) · Oncotarget · doi:10.18632/oncotarget.137 · Cited by 114
Cited by
Comprehensive molecular characterization of urothelial bladder carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/za09-dk57 · Cited by 2,990
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Knowles, M. A., & Hurst, C. D. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3817 · Cited by 1,247
Self-citationThe landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer
Lee, S. H., Hu, W., Matulay, J. T., Silva, M. V., Owczarek, T. B., Kim, K., Chua, C. W., Barlow, L. J., Kandoth, C., Williams, A. B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.017 · Cited by 873
Metadata
- Authors
- Williams, S. V., Hurst, C. D., & Knowles, M. A.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-11-21
- Volume
- 22
- Issue
- 4
- Pages
- 795-803
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2113235293
- Cited by
- 390
- References
- 25
- FWCI
- 13.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oncogenic FGFR3 gene fusions in bladder cancer. https://app.cochat.ai/papers/10.1093/hmg/dds486
- The paper
- Williams, S. V., Hurst, C. D., & Knowles, M. A. (2013). Oncogenic FGFR3 gene fusions in bladder cancer. Human Molecular Genetics. https://doi.org/10.1093/hmg/dds486
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.